Header Logo

Connection

SETH LERNER to Drug Carriers

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Drug Carriers.
SETH LERNER
Connection Strength
0.669
Drug Carriers
  1. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
    View in: PubMed
    Score: 0.669
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.